New drug combo targets tough breast cancer

NCT ID NCT04572295

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 30 times

Summary

This early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a specific type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and understand side effects. About 51 participants will take part to help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Eisai Trial Site 1

    Koto-ku, Tokyo, Japan

  • Eisai Trial Site 10

    Kitaadachi-gun, Saitama, Japan

  • Eisai Trial Site 11

    Nagoya, Aichi-ken, Japan

  • Eisai Trial Site 2

    Shinagawa-ku, Tokyo, Japan

  • Eisai Trial Site 3

    Chuo-ku, Tokyo, Japan

  • Eisai Trial Site 4

    Sendai, Miyagi, Japan

  • Eisai Trial Site 5

    Yokohama, Kanagawa, Japan

  • Eisai Trial Site 6

    Kashiwa, Chiba, Japan

  • Eisai Trial Site 7

    Chuo-ku, Osaka, Japan

  • Eisai Trial Site 8

    Shinjuku-ku, Tokyo, Japan

  • Eisai Trial Site 9

    Matsuyama, Ehime, Japan

Conditions

Explore the condition pages connected to this study.